- Home
- TKO vs ROIV Comparison
TKO vs ROIV Comparison
Compare TKO & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKO
- ROIV
- Stock Information
- Founded
- TKO 1980
- ROIV 2014
- Country
- TKO United States
- ROIV United Kingdom
- Employees
- TKO N/A
- ROIV N/A
- Industry
- TKO
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- TKO
- ROIV Health Care
- Exchange
- TKO Nasdaq
- ROIV Nasdaq
- Market Cap
- TKO 9.7B
- ROIV 8.4B
- IPO Year
- TKO N/A
- ROIV N/A
- Fundamental
- Price
- TKO $143.19
- ROIV $10.94
- Analyst Decision
- TKO Strong Buy
- ROIV Strong Buy
- Analyst Count
- TKO 14
- ROIV 8
- Target Price
- TKO $140.86
- ROIV $17.93
- AVG Volume (30 Days)
- TKO 800.2K
- ROIV 5.3M
- Earning Date
- TKO 02-27-2025
- ROIV 02-11-2025
- Dividend Yield
- TKO N/A
- ROIV N/A
- EPS Growth
- TKO N/A
- ROIV N/A
- EPS
- TKO N/A
- ROIV 5.89
- Revenue
- TKO $2,776,140,000.00
- ROIV $129,128,999.00
- Revenue This Year
- TKO $66.81
- ROIV $15.98
- Revenue Next Year
- TKO $13.24
- ROIV N/A
- P/E Ratio
- TKO N/A
- ROIV $1.86
- Revenue Growth
- TKO 108.30
- ROIV 145.68
- 52 Week Low
- TKO $75.35
- ROIV $9.69
- 52 Week High
- TKO $149.40
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- TKO 56.51
- ROIV 38.75
- Support Level
- TKO $137.50
- ROIV $10.42
- Resistance Level
- TKO $147.45
- ROIV $11.82
- Average True Range (ATR)
- TKO 3.65
- ROIV 0.35
- MACD
- TKO -0.70
- ROIV -0.11
- Stochastic Oscillator
- TKO 57.19
- ROIV 29.21
About TKO TKO Group Holdings Inc.
TKO Group Holdings Inc is a premium sports and entertainment company that comprises UFC, the world's mixed martial arts organization, and WWE, an integrated media organization and the recognized leader in sports entertainment.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.